Intas has developed a biosimilar of Lucentis, which is currently under Phase III global trial for submission in major countries including EMA & the US
The companies will continue with their exclusive agreements, including commercialization of their current portfolio
The virtual world makes it possible to visualize, test, understand and predict what cannot be seen, before a patient is treated
It becomes the first ophthalmology biosimilar to gain FDA approval in the United States
Subscribe To Our Newsletter & Stay Updated
